Cargando…

ATI-2307 Exhibits Equivalent Antifungal Activity in Cryptococcus neoformans Clinical Isolates With High and Low Fluconazole IC(50)

Half maximal inhibitory concentrations (IC(50)) to the experimental drug ATI-2307 and complete inhibition (IC(90)) of the common clinically used antifungal drug amphotericin B were determined by microbroth dilution assay for a collection of 69 clinical isolates of Cryptococcus neoformans from Uganda...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gerlach, Elliot S., Altamirano, Sophie, Yoder, J. Marina, Luggya, Tony S., Akampurira, Andrew, Meya, David B., Boulware, David R., Rhein, Joshua, Nielsen, Kirsten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262267/ https://www.ncbi.nlm.nih.gov/pubmed/34249782 http://dx.doi.org/10.3389/fcimb.2021.695240

Ejemplares similares

829. 5-Flucytosine Longitudinal Antifungal Susceptibility Testing of Cryptococcus neoformans: A Sub-study of the EnACT Trial Testing Oral Amphotericin
por: McHale, Thomas, et al.
Publicado: (2023)

Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
por: Giamberardino, Charles D., et al.
Publicado: (2023)

2120. Minimum Inhibitory Concentration Distribution of Fluconazole against Cryptococcus Species and the Fluconazole Exposure Prediction Model
por: Chesdachai, Supavit, et al.
Publicado: (2019)

Minimum Inhibitory Concentration Distribution of Fluconazole Against Cryptococcus Species and the Fluconazole Exposure Prediction Model
por: Chesdachai, Supavit, et al.
Publicado: (2019)

Colony and Single Cell Level Analysis of the Heterogeneous Response of Cryptococcus neoformans to Fluconazole
por: Altamirano, Sophie, et al.
Publicado: (2018)

Lack of Association between Fluconazole Susceptibility and ERG11 Nucleotide Polymorphisms in Cryptococcus neoformans Clinical Isolates from Uganda
por: Atim, Priscilla Belbir, et al.
Publicado: (2022)

605. Efficacy and pharmacokinetics-pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis
por: Giamberardino, Charles D, et al.
Publicado: (2022)

Low Glucose Mediated Fluconazole Tolerance in Cryptococcus neoformans
por: Bhattacharya, Somanon, et al.
Publicado: (2021)

Antifungal Susceptibilities of Cryptococcus neoformans
por: Archibald, Lennox K., et al.
Publicado: (2004)

Identification of Pathogen Genomic Differences That Impact Human Immune Response and Disease during Cryptococcus neoformans Infection
por: Gerstein, Aleeza C., et al.
Publicado: (2019)

Coregulation of extracellular vesicle production and fluconazole susceptibility in Cryptococcus neoformans
por: Rizzo, Juliana, et al.
Publicado: (2023)

Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates
por: Rossi, Suélen A., et al.
Publicado: (2016)

Fluconazole-Induced Ploidy Change in Cryptococcus neoformans Results from the Uncoupling of Cell Growth and Nuclear Division
por: Altamirano, Sophie, et al.
Publicado: (2017)

Fluconazole induces ROS in Cryptococcus neoformans and contributes to DNA damage in vitro
por: Peng, Congyue Annie, et al.
Publicado: (2018)

Effects of environmental factors on sensitivity of Cryptococcus neoformans to fluconazole and amphotericin B
por: Carlson, Tyler, et al.
Publicado: (2021)

Novel ABC Transporter Associated with Fluconazole Resistance in Aging of Cryptococcus neoformans
por: Oliveira, Natalia Kronbauer, et al.
Publicado: (2022)

Corrigendum: Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates
por: Rossi, Suélen A., et al.
Publicado: (2016)

P092 Otilonium bromide is a potent antifungal agent against fluconazole- and flucytosine-resistant Cryptococcus neoformans strains
por: Zhen, Cheng, et al.
Publicado: (2022)

Cryptococcus neoformans Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis
por: Robertson, Emma J., et al.
Publicado: (2014)

Necrotizing fasciitis as the initial presentation of disseminated infection with fluconazole-resistant Cryptococcus neoformans
por: Richardson, Timothy E, et al.
Publicado: (2014)

Antiphagocytic protein 1 increases the susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole
por: Ghaffar, Muhammad, et al.
Publicado: (2019)

Increase of reactive oxygen species contributes to growth inhibition by fluconazole in Cryptococcus neoformans
por: Dbouk, Nadir Hani, et al.
Publicado: (2019)

Interactions between antifungals and everolimus against Cryptococcus neoformans
por: Liang, Pin, et al.
Publicado: (2023)

Novel Antifungal Activity for the Lectin Scytovirin: Inhibition of Cryptococcus neoformans and Cryptococcus gattii
por: Jones, Tyler H., et al.
Publicado: (2017)

Characterization of the Chromosome 4 Genes That Affect Fluconazole-Induced Disomy Formation in Cryptococcus neoformans
por: Ngamskulrungroj, Popchai, et al.
Publicado: (2012)

The interplay of phenotype and genotype in Cryptococcus neoformans disease
por: Altamirano, Sophie, et al.
Publicado: (2020)

Antifungal activity of liriodenine on clinical strains of Cryptococcus neoformans and Cryptococcus gattii species complexes
por: Levorato-Vinche, Adriele Dandara, et al.
Publicado: (2022)

Antifungal potential of punicalagin against Cryptococcus neoformans species complex
por: Silva, Thaísa Cristina, et al.
Publicado: (2018)

Structure and inhibition of Cryptococcus neoformans sterylglucosidase to develop antifungal agents
por: Pereira de Sa, Nivea, et al.
Publicado: (2021)

The Environmental Effects on Virulence Factors and the Antifungal Susceptibility of Cryptococcus neoformans
por: Momin, Mahek, et al.
Publicado: (2021)

Minocycline and Fluconazole Have a Synergistic Effect Against Cryptococcus neoformans Both in vitro and in vivo
por: Kong, Qinxiang, et al.
Publicado: (2020)

Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade
por: Naicker, Serisha D., et al.
Publicado: (2020)

Adaptation to Fluconazole via Aneuploidy Enables Cross-Adaptation to Amphotericin B and Flucytosine in Cryptococcus neoformans
por: Yang, Feng, et al.
Publicado: (2021)

Combined effect of furanone fluconazole and amphotericin B against biofilms formed from Cryptococcus neoformans
por: Meenakumari, Kirishnamoorthy, et al.
Publicado: (2021)

S8.5d Cryptococcus neoformans and Cryptococcus gattii clinical isolates from Colombia develop heteroresistance to fluconazole at high concentrations
por: Melendres, Javier, et al.
Publicado: (2022)

The Cryptococcus neoformans Transcriptome at the Site of Human Meningitis
por: Chen, Yuan, et al.
Publicado: (2014)

Investigation of Antifungal Mechanisms of Thymol in the Human Fungal Pathogen, Cryptococcus neoformans
por: Jung, Kwang-Woo, et al.
Publicado: (2021)

Antifungal activity of dendritic cell lysosomal proteins against Cryptococcus neoformans
por: Nelson, Benjamin N., et al.
Publicado: (2021)

Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A
por: Florio, Ada Rita, et al.
Publicado: (2011)

Antifungal and Anti-Biofilm Activity of Essential Oil Active Components against Cryptococcus neoformans and Cryptococcus laurentii
por: Kumari, Poonam, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_e9s6b89a0ti3trghseatu7mph0